A Phase 3, randomized, open-label study of upfront camizestrant vs standard endocrine therapy as adjuvant treatment for ER-positive/HER2negative early breast cancer with intermediate-high or high risk of recurrence (CAMBRIA-2)

被引：0
|
作者：
Loibl, Sibylle
Park, Yeon
Tolaney, Sara
Gioni, Ioanna
Johnston, Simon
Klinowska, Teresa
Mayer, Ingrid A.
Nunes, Raquel
Pistilli, Barbara
Stuart, Mary
Quintana, Angela
Walding, Andrew
Gnant, Michael
机构：
来源：
CANCER RESEARCH | 2024年 / 84卷 / 09期
关键词：
D O I：
10.1158/1538-7445.SABCS23-PO4-27-07
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO4-27-07
引用
收藏
页数：3
相关论文
共 50 条
  • [21] ER-positive breast cancer patients with more than three positive nodes or grade 3 tumors are at high risk of late recurrence after 5-year adjuvant endocrine therapy
    Song, Fangbin
    Zhang, Jianbing
    Li, Shanbao
    Wu, Junyi
    Jin, Tao
    Qin, Jun
    Wang, Ye
    Wang, Min
    Xu, Junming
    ONCOTARGETS AND THERAPY, 2017, 10 : 4859 - 4867
  • [22] A phase 2 open label study of everolimus in combination with endocrine therapy in resistant hormone receptor-positive HER2-negative advanced breast cancer
    Yardley, D. A.
    Blakely, L.
    Hemphill, B.
    Joseph, M.
    Liggett, W.
    Daniel, B.
    Castrellon, A.
    Shastry, M.
    Finney, L.
    DeBusk, L.
    Hainsworth, J. D.
    Burris, H. A., III
    CANCER RESEARCH, 2017, 77
  • [23] Impact of the 21-gene assay on treatment decisions in high-risk patients with ER-positive HER2-negative early breast cancer: Results of the KARMA Dx study
    Llombart, A.
    Andres, R.
    Anton Torres, A.
    Martinez, N.
    Rodriguez, C.
    Sanchez-Rovira, P.
    Rojas, B.
    Ruiz Borrego, M.
    Bermejo, B.
    Martinez de Duenas, E.
    ANNALS OF ONCOLOGY, 2019, 30
  • [24] PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2 positive metastatic breast cancer
    Metzger-Filho, Otto
    Mandrekar, Sumithra
    Loibl, Sibylle
    Ciruelos, Eva
    Gianni, Luca
    Lim, Elgene
    Miller, Kathy
    Huang, Cynthia
    Koehler, Maria
    Francis, Prue
    Valagussa, Pinuccia
    Goel, Shom
    Prat, Aleix
    Goetz, Matthew
    Loi, Sherene
    Krop, Ian
    Carey, Lisa
    Lanzillotti, Jane
    Winer, Eric
    Tripathy, Debu
    DeMichele, Angela
    CANCER RESEARCH, 2018, 78 (04)
  • [25] PATINA: A randomized open label phase III trial to evaluate the efficacy and safety of palbociclib + anti HER2 therapy + endocrine therapy vs anti HER2 therapy + endocrine therapy after induction treatment for hormone receptor positive, HER2-positive metastatic breast cancer
    Metzger, O.
    Mandrekar, S.
    Ciruelos, E.
    Loibl, S.
    Valagussa, P.
    Demichele, A. M.
    Lim, E.
    Tripathy, D.
    Winer, E.
    Huang, C.
    Khoeler, M.
    Carey, L.
    Francis, P.
    Miller, K.
    Goel, S.
    Goetz, M. P.
    Prat, A.
    Loi, S.
    Krop, I.
    Gianni, L.
    ANNALS OF ONCOLOGY, 2017, 28
  • [26] Apatinib combined with docetaxel and platinum as neoadjuvant treatment for triple-negative/HER2-positive breast cancer: A randomized, open-label, multicenter, phase 2 trial
    Liu, Yunjiang
    Zhang, Shuo
    CANCER RESEARCH, 2020, 80 (04)
  • [27] Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)
    Johnston, Stephen R. D.
    Harbeck, Nadia
    Hegg, Roberto
    Toi, Masakazu
    Martin, Miguel
    Shao, Zhi Min
    Zhang, Qing Yuan
    Martinez Rodriguez, Jorge Luis
    Campone, Mario
    Hamilton, Erika
    Sohn, Joohyuk
    Guarneri, Valentina
    Okada, Morihito
    Boyle, Frances
    Neven, Patrick
    Cortes, Javier
    Huober, Jens
    Wardley, Andrew
    Tolaney, Sara M.
    Cicin, Irfan
    Smith, Ian C.
    Frenzel, Martin
    Headley, Desiree
    Wei, Ran
    San Antonio, Belen
    Hulstijn, Maarten
    Cox, Joanne
    O'Shaughnessy, Joyce
    Rastogi, Priya
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (34) : 3987 - 3998
  • [28] A randomized, open-label, parallel-group, multicenter phase 2 study comparing the efficacy and safety of oral AZD9833 versus fulvestrant in women with advanced ER-positive HER2-negative breast cancer (SERENA-2)
    Oliveira, Mafalda
    Bennett, Maxine
    Khalil, Ali
    Mather, Richard
    Maudsley, Rhiannon
    McGuinness, Sam
    Morrow, Christopher J.
    Sykes, Andy
    Zhang, Li
    Klinowska, Teresa
    Lindemann, Justin P. O.
    Carroll, Danielle
    CANCER RESEARCH, 2021, 81 (04)
  • [29] Camizestrant, a Next Generation Oral SERD, vs Fulvestrant in Post-Menopausal Women With Advanced ER-Positive HER2-Negative Breast Cancer: Results of the Randomized, Multi-Dose Phase 2 SERENA-2 Trial
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2023, 21 (02) : 12 - 12
  • [30] Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial
    Oliveira, Mafalda
    Pominchuck, Denys
    Nowecki, Zbigniew
    Hamilton, Erika
    Kulyaba, Yaroslav
    Andabekov, Timur
    Hotko, Yevhen
    Melkadze, Tamar
    Nemsadze, Gia
    Neven, Patrick
    Semegen, Yuriy
    Vladmirov, Vladmir
    Zamagni, Claudio
    Denys, Hannelore
    Forget, Frederic
    Horvath, Zsolt
    Nesterova, Alfiya
    Bennett, Maxine
    Kirova, Bistra
    Klinowska, Teresa
    Lindemann, Justin
    Lissa, Delphine
    Mathewson, Alastair
    Morrow, Christopher
    Traugottova, Zuzana
    Van Zyl, Ruaan
    Arkania, Ekaterine
    CANCER RESEARCH, 2023, 83 (05)
12345